

Pl 1140681

REC'D 08 MAR 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 04, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/435,445

FILING DATE: December 20, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/41391



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Tarver

M. TARVER
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL

for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80.00

Complete if Known

Application Number	Unknown
Filing Date	12/20/2002
First Named Inventor	Smith, Thomas J.
Examiner Name	Unknown
Art Unit	Unknown
Attorney Docket No.	TJS - 005

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number
Deposit Account Name

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 740	2001 370	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 510	2003 255	Plant filing fee	
1004 740	2004 370	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	80.00

SUBTOTAL (1) (\$) 80.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims -20** = X =
Independent Claims -3** = X =
Multiple Dependent =

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 84	2201 42	Independent claims in excess of 3	
1203 280	2203 140	Multiple dependent claim, if not paid	
1204 84	2204 42	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 400	2252 200	Extension for reply within second month	
1253 920	2253 460	Extension for reply within third month	
1254 1,440	2254 720	Extension for reply within fourth month	
1255 1,960	2255 980	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,280	2453 640	Petition to revive - unintentional	
1501 1,280	2501 640	Utility issue fee (or reissue)	
1502 460	2502 230	Design issue fee	
1503 620	2503 310	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1808 180	1808 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 740	2809 370	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 740	2810 370	For each additional invention to be examined (37 CFR 1.129(b))	
1801 740	2801 370	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type)	Lisa M. Portscher	Registration No. (Attorney/Agent)	N/A	Telephone	617-361-5434
Signature	<i>Lisa M. Portscher</i>	Date	12/20/02		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**LARGE CRYSTALLINE FORMULATIONS FOR
SUSTAINED RELEASE DELIVERY OF ANGIOTENSIN II RECEPTOR
ANTAGONISTS**

BACKGROUND OF THE INVENTION

Field of the Invention.

This invention relates to the field of pharmaceutical sciences, and particularly to the formulation of sustained-release drug delivery systems for angiotensin II receptor antagonists.

Description of the Related Art.

1. Angiotensin II receptor antagonists

Angiotensin II receptor antagonists are compounds which interfere with the activity of angiotensin II by binding to angiotensin II receptors and interfering with its activity. Angiotensin II receptor antagonists are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias.

2. Oral and IV Formulations

Drugs of the class known as angiotensin II receptor antagonists are formulated for oral ingestion or intravenous (IV) injection. Therefore it is essential that the drugs dissolve into the gastro-intestinal or IV fluids in order to be absorbed into the body. For this reason small particles have either been mixed with binding agents and pressed into pills or tablets for oral administration or dissolved in physiologically acceptable aqueous solvents for IV administration. Small particles have generally been preferred because of their more rapid dissolution

According to the Noyes Whitney Equation:

$$dc/dt = kS (C_s - C_t) \quad (1)$$

where dc/dt is the rate of dissolution, k is the dissolution rate constant, S is the surface area of the dissolving solid, C_s is the saturation concentration of drug in the diffusion layer and C_t is the concentration of drug in the dissolution media (or the bulk).

Of the variables in equation 1, only the surface area, S , is easily manipulated and, therefore, it is S which ultimately determines the rate of dissolution and drug delivery. In the prior art, angiotensin II receptor antagonists have been formulated as small particles by milling in order to increase the surface area-to-volume ratio and therefore aid in rapid dissolution.

Furthermore, many drugs can be formulated as one of several polymorphs in order to alter their stability and dissolution properties. Polymorphism is the chemical characteristic of solid substances that can exist in one or more crystalline and/or amorphous forms. The different polymorphs are usually designated by Roman numerals, with the most stable polymorph under ambient conditions being designated as Form I. In order to increase their dissolution, some drugs are formulated as less stable polymorphs or as amorphous forms.

3. Sustained Release Formulations

In certain situations, it is desired that an angiotensin II receptor antagonist be administered in a sustained release formulation, typically with the objectives of achieving a nearly constant, or zero order, release rate over a significant period of time and reducing the problem of non-compliance or non-adherence to therapy. Most sustained release systems employ a finely milled or micronized preparation of the active pharmaceutical ingredient as a starting point in the formulations. The release of the active pharmaceutical ingredient into the body is then controlled using matrices, membranes or other inactive ingredients or devices. Examples of methods and devices known in the art for sustained release formulations include liposomes, bioerodable matrices (e.g., PLA/PGLA matrices), drug-permeable implants (e.g., U.S. Pat. No. 3,993,073 to Zaffaroni), implants with drug-permeable and drug-impermeable membranes (e.g., U.S. Pat. No. 5,378,475 to Smith et al.), and osmotic drug delivery systems (e.g., U.S. Pat. No. 4,439,196 to Higuchi).

The production and use of pharmaceutical preparations including larger drug particles to sustain delivery have been described in the art for certain antibiotics, insulin and steroids (see, e.g., (Ansel 1999); and (Gennaro 2000), but the use of this technique has not been applied to the delivery of angiotensin II receptor antagonists.

For example, suspensions of crystals of benzathine and procaine penicillin are useful in the treatment of rheumatic fever and other infections. Typically, therapeutic levels of these antibiotics can be sustained for 14-28 days after a single IM injection (Cadorniga, Burgos et al. 1991) (Kaplan, Berrios et al. 1989).

Similarly, suspensions of crystals of zinc insulins have slow release properties that depend on crystal size (Nichols 2000). The principal determinant of sustained antiglycemic action in these slow-release or "lente" insulin preparations is the dissolution of the insulin crystals.

Sustained release suspensions of corticosteroids for local delivery (intralesional, intra-articular) or systemic delivery achieve their duration of action due to slow dissolution of crystals of insoluble salts (Mollmann, Bigalke et al. 1977).

There remains a need, however, for new and improved methods and products for the sustained release delivery of angiotensin II receptor antagonists.

SUMMARY OF THE INVENTION

The present invention is generally directed to the production and use of pharmaceutical preparations including large and/or shape-controlled coated or uncoated crystalline formulations for the purpose of sustained-release delivery of angiotensin II receptor antagonists. The invention depends, in part, upon the recognition that, if a larger crystal of a drug is introduced, there will be a sustained release effect due to the decreased surface area-to-volume ratio of the larger particles. In addition, if the particle is formulated to be substantially flat, then the kinetics of drug release can be made to approach zero order or linear delivery. Moreover, formulation using the most stable polymorph (Form I) will aid in sustaining release because of decreased solubility from the surface, and will also increase the chemical stability of the active pharmaceutical ingredient. Furthermore, the coating of the particle with a semi-permeable membrane can cause the delivery rate to be predicated by the difference in the concentration of drug in solution between the inside and outside of the coating. The chemical potential difference

between the inside and outside will be constant as long as the solution is saturated inside and at a "sink" concentration outside. In the present invention, such conditions will apply for the majority of the drug delivery time period, therefore causing sustained pseudo-zero order delivery.

In some embodiments of the invention, the crystals have at least one linear dimension greater than 50 μ m, greater than 100 μ m, greater than 500 μ m, or greater than 1mm. In some embodiments in which the formulations are heterogeneous with respect to crystal size, at least 70%, 80%, 90% or 95% of the crystals have at least one linear dimension greater than 50 μ m, greater than 100 μ m, greater than 500 μ m, or greater than 1mm.

In some embodiments, the formulations are produced as bodies which are relatively thin in one dimension relative to perpendicular dimensions, such as substantially flat or disc-shaped bodies.

In some embodiments, the active pharmaceutical ingredient is crystallized in a stable crystalline form, or the most stable of multiple crystalline forms.

In some embodiments, the pharmaceutical preparation of the invention is a surgically implantable or injectable (via a needle/trochar) implant.

In some embodiments, the pharmaceutical preparation of the invention is an injectable suspension.

In some embodiments, the crystals are uncoated.

In some embodiments, the crystals are coated with a biodegradable semi-permeable polymer coating. In specific embodiments, the coating can be PLA; PLGA; a polyorthoester; or a polyanhydride.

In some embodiments, the crystals are coated with a biocompatible semi-permeable polymer coating. In specific embodiments, the coating can be PVA; EVA; or silicone.

In another aspect, the invention provides methods for treating a mammal suffering from or at risk of a condition for which administration of an angiotensin II receptor antagonist is indicated. The methods involve administering a pharmaceutical preparation of the invention to the mammal such that an effective amount of the active pharmaceutical ingredient is provided over a sustained period of time.

In another aspect, the invention provides a pharmaceutical preparation and kits comprising large crystalline particles. In some embodiments, the large crystalline particles are in a dry form that can be suspended in a separately provided diluent prior to use. In some embodiments, a kit is provided containing separate containers of the large crystalline particles in a dry form and a diluent for forming the suspension prior to use. In other embodiments, a multi-chambered product is provided in which the large crystalline particles are contained in one chamber in a dry form and a diluent is contained in another chamber, such that a suspension is formed when the wall separating the chambers is ruptured and the particles and diluent are mixed.

DETAILED DESCRIPTION

General Considerations.

The present invention is generally directed to the production and use of pharmaceutical preparations including large crystalline formulations for the purpose of sustained-release delivery of angiotensin II receptor antagonists. In contrast to the teachings of the prior art, the present invention is dependent, in part, upon the discovery that large crystalline formulations of these active pharmaceutical ingredients, employing crystals having linear dimensions exceeding 50 μ m, 100 μ m, 500 μ m, or even 1mm, are useful for sustained-release drug delivery. Moreover, it has been discovered that such large crystalline formulations can be produced in flattened shapes (i.e., shapes in which the body is substantially smaller in one linear dimension relative to perpendicular dimensions) which dissolve with pseudo-zero order kinetics. Furthermore, the coating of such crystals can enhance the linearity of release. Some active pharmaceutical ingredients can exist in multiple crystalline forms. For such active ingredients, it has been discovered that the stable or most stable form is the most useful for sustained release drug delivery.

Definitions.

All technical and scientific terms used herein, unless otherwise defined below, are intended to have the same meaning as commonly understood by one of ordinary skill in the art; references to techniques employed herein are intended to refer to the techniques

as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques which would be apparent to one of skill in the art. In order to more clearly and concisely describe the subject matter which is the invention, the following definitions are provided for certain terms which are used in the specification.

The term "pharmaceutically acceptable carrier" as used herein means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the active pharmaceutical ingredients from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient (i.e., suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit/risk ratio).

As used herein, the term "effective amount" of an active pharmaceutical ingredient means the total amount of the active pharmaceutical ingredient in a composition that is sufficient to cause a statistically significant change of a detectable biochemical or phenotypic characteristic. When applied to an individual active pharmaceutical ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active pharmaceutical ingredients that result in the effect, whether administered in combination, serially or simultaneously.

As used herein, the term "substantially pure" means a preparation which contains at least 60% (by dry weight) of the active pharmaceutical ingredient of interest, exclusive of the weight of other intentionally included compounds. In certain embodiments, the preparation is at least 75%, at least 90%, or at least 99% the active pharmaceutical ingredient of interest by dry weight, exclusive of the weight of other intentionally included compounds. Purity can be measured by any appropriate method, e.g., column chromatography, gel electrophoresis, amino acid compositional analysis or HPLC analysis. If a preparation intentionally includes two or more different active pharmaceutical ingredients of the invention, a "substantially pure" preparation means a

preparation in which the total dry weight of the active pharmaceutical ingredients of the invention is at least 60% of the total dry weight, exclusive of the weight of other intentionally included compounds. For preparations containing two or more active pharmaceutical ingredients of the invention, the total weight of the active pharmaceutical ingredients of the invention should be at least 75%, at least 90%, or at least 99%, of the total dry weight of the preparation, exclusive of the weight of other intentionally included compounds. Thus, if the active pharmaceutical ingredients of the invention are mixed with one or more other compounds (e.g., diluents, stabilizers, detergents, excipients, salts, sugars, lipids) for purposes of administration, stability, storage, and the like, the weight of such other compounds is ignored in the calculation of the purity of the preparation.

As used herein, the term "mammalian subject" means any member of the class Mammalia including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.

As used herein, the terms "modulate" or "affect" mean to either increase or decrease. As used herein, the terms "increase" and "decrease" mean, respectively, statistically significantly increase (*i.e.*, $p < 0.5$) and statistically significantly decrease (*i.e.*, $p < 0.5$).

As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can equal each integer value of the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can equal each real value of the numerical range, including the end-points of the range. As an example, a variable which is described as having values between 0 and 2, can be 0, 1 or 2 for variables which are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value ≤ 2 for variables which are inherently continuous.

As used herein, unless specifically indicated otherwise, the word "or" is used in the "inclusive" sense of "and/or" and not the "exclusive" sense of "either/or."

Crystal Size.

In one aspect, the invention provides pharmaceutical formulations in which the active pharmaceutical ingredient is in the form of large crystals. This distinguishes the formulations of the invention from prior art formulations in which active ingredients are machined or milled to produce small or micronized crystals of the drug, which then must be combined with matrices, semi-permeable membranes, pumps or other inactive ingredients or devices in order to achieve the effect of sustained release delivery.

In some embodiments, the crystals have at least one linear dimension greater than 50 μ m, greater than 100 μ m, greater than 500 μ m, or greater than 1mm. In some embodiments in which the formulations are heterogeneous with respect to crystal size, at least 70%, 80, 90% or 95% of the crystals have at least one linear dimension greater than 50 μ m, greater than 100 μ m, greater than 500 μ m, or greater than 1mm.

Body Shape.

The shape of a solid formulation, including implants or solid bodies that may be present in a liquid suspension, can be described by reference to three perpendicular or orthogonal axes. In some embodiments, the formulations are produced as bodies which are substantially smaller in one dimension relative to perpendicular dimensions, such as substantially flat or disc-shaped bodies. Such bodies will present a more constant surface area over time during dissolution. Because dissolution occurs at the surface of the body, such relatively constant surface areas are useful to approximate or achieve pseudo-zero order kinetics of delivery.

Crystal Form.

Polymorphism is the chemical characteristic of solid substances that can exist in one or more crystalline and/or amorphous forms. The different polymorphs are usually designated by Roman numerals, with the most stable polymorph under ambient conditions being designated as Form I.

In some embodiments, the active pharmaceutical ingredient is crystallized in a stable crystalline form, or the most stable of multiple crystalline forms (e.g., Form I). Because this crystalline form tends to be the least soluble in water, it has been avoided in the prior art. However, it has been discovered that utilizing the most stable polymorph can significantly enhance the ability to achieve sustained release rates.

Active Pharmaceutical Ingredients.

Active pharmaceutical ingredients which may be formulated according to the invention include any angiotensin II receptor antagonist drug which may be crystallized according to the invention. Angiotensin II receptor antagonists are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias. Angiotensin II receptor antagonists are compounds which interfere with the activity of angiotensin II by binding to angiotensin II receptors and interfering with its activity. Angiotensin II receptor antagonists are well known and include peptide compounds and non-peptide compounds. Most angiotensin II receptor antagonists are slightly modified congeners in which agonist activity is attenuated by replacement of phenylalanine in position 8 with some other amino acid; stability can be enhanced by other replacements that slow degeneration in vivo. Examples of angiotensin II receptor antagonists include: peptidic compounds (e.g., saralasin, [(San.sup.1)(Val.sup.5)(Ala.sup.8)] angiotensin -(1-8) octapeptide and related analogs); N-substituted imidazole-2-one (U.S. Pat. No. 5,087,634); imidazole acetate derivatives including 2-N-butyl-4-chloro-1-(2-chlorobenzile) imidazole-5-acetic acid (Wong, Chiu et al. 1988); 4, 5, 6, 7-tetrahydro-1H-imidazo [4, 5-c] pyridine-6-carboxylic acid and analog derivatives (U.S. Pat. No. 4,816,463); N2-tetrazole beta-glucuronide analogs (U.S. Pat. No. 5,085,992); substituted pyrroles, pyrazoles, and tryazoles (U.S. Pat. No. 5,081,127); phenol and heterocyclic derivatives such as 1, 3-imidazoles (U.S. Pat. No. 5,073,566); imidazo-fused 7-member ring heterocycles (U.S. Pat. No. 5,064,825); peptides (e.g., U.S. Pat. No. 4,772,684); antibodies to angiotensin II (e.g., U.S. Pat. No. 4,302,386); and aralkyl imidazole compounds such as biphenyl-methyl substituted imidazoles (e.g., EP Number 253,310, Jan. 20, 1988); ES8891 (N-morpholinoacetyl-(-1-naphthyl)-L-alany- 1-(4,

thiazolyl)-L-alanyl (3S, 4S)-4-amino-3-hydroxy-5-cyclo-hexapentanoyl- -N-hexylamide, Sankyo Company, Ltd., Tokyo, Japan); SKF108566 (E-alpha-2-[2-butyl-1-(carboxy phenyl) methyl] 1H-imidazole-5-yl[methylan- e]-2-thiophenepropanoic acid, Smith Kline Beecham Pharmaceuticals, PA); Losartan (DUP753/MK954, DuPont Merck Pharmaceutical Company); Remikirin (RO42-5892, F. Hoffman LaRoche AG); A.sub.2 agonists (Marion Merrill Dow) and certain non-peptide heterocycles (G.D. Searle and Company). The above compounds and all pharmaceutically acceptable salts thereof are incorporated by reference.

Production of Large Crystalline Formulations.

The large crystalline formulations of the invention, although not produced in the prior art, can be produced by methods well known in the art. The active pharmaceutical ingredients in the formulations can be any angiotensin II receptor antagonist for which the large crystalline formulations of the invention can be produced.

1. Solvation Crystallization.

A substantially pure pharmaceutical preparation of the angiotensin II receptor antagonist drug is synthesized, isolated or otherwise obtained. The purity is tested to ensure suitability for use in a pharmaceutical preparation.

The active pharmaceutical ingredient is dissolved in an appropriate volatile solvent to form a solution. The solution is then dispensed into properly shaped drying areas, such as flat-bottomed wells or flat or dimpled surfaces. The solvent is then allowed to evaporate at an appropriate rate (e.g., controlling the rate by controlling the temperature and/or the humidity and/or the partial pressure of the solvent or other gases in the ambient atmosphere) to obtain crystals of the desired size.

Alternatively the solution of active pharmaceutical ingredient in solvate is sprayed onto a cooling slab surface. A disc is formed by evaporation of the solvent and the disc parameters (e.g., size, shape, weight) are adjusted by adjusting the parameters of the spraying step (e.g., volume of drops, concentration, ambient pressure and temperature, slab temperature, velocity of spray, nozzle size, etc.).

The resultant crystals are sorted by size and/or subjected to mechanical forces to modify the size or shape of the crystalline bodies. For example, the bodies can be passed

through sieves to isolate bodies within desired size ranges, and can be ground, lathed, milled, cut (e.g., with a laser), etc., to reduce the size of alter the shape of the bodies.

2. Melting and Recrystallization.

A substantially pure pharmaceutical preparation of the angiotensin II receptor antagonist drug is synthesized, isolated or otherwise obtained. The purity is tested to ensure suitability for use in a pharmaceutical preparation.

The melting point of the active pharmaceutical ingredient is determined by standard methods (e.g., visual inspection while slowly increasing or decreasing ambient temperature and/or by reference to the literature). For each active pharmaceutical ingredient, the optimum melting process is that which melts the drug completely while minimizing molecular breakdown. This optimum process can be determined for each active pharmaceutical ingredient by one skilled in the art through the process of varying key parameters in the melting process (e.g., rate, intensity, agitation or mixing, etc.). The results of the process can be assessed by determining the purity of the resulting melted form (i.e., lack of molecular breakdown) through HPLC or NMR analysis. After melting, the active pharmaceutical ingredient is cooled, actively or passively, so as to promote the formation of large crystals of the desired crystalline form (e.g., Form I). Optimum cooling parameters and process (e.g., mixing, rate of cooling, final temperature, cooling substrate or surface characteristics, etc.) can be determined by varying these parameters experimentally and characterizing the resultant crystals in terms of size, shape and polymorph state.

The resultant crystals can then be sorted by size and/or subjected to mechanical forces to modify the size or shape of the crystalline bodies. For example, the bodies can be passed through sieves to isolate bodies within desired size ranges, and can be ground, lathed, milled, cut (e.g., with a laser), etc., to reduce the size or alter the shape of the bodies.

3. Seed Crystallization.

A substantially pure pharmaceutical preparation of the angiotensin II receptor antagonist is synthesized, isolated or otherwise obtained. The purity is tested to ensure suitability for use in a pharmaceutical preparation.

The active pharmaceutical ingredient is dissolved in an appropriate solvent to achieve a saturated solution. The saturated solution is then seeded with a crystal of the active pharmaceutical ingredient to initiate crystal formation from the saturated solution. The crystals are then harvested (e.g., by straining from solution and drying, or by evaporating the solvent).

The resultant crystals can then be sorted by size and/or subjected to mechanical forces to modify the size or shape of the crystalline bodies. For example, the bodies can be passed through sieves to isolate bodies within desired size ranges, and can be ground, lathed, milled, cut (e.g., with a laser), etc., to reduce the size of alter the shape of the bodies.

4. Pressure.

A substantially pure pharmaceutical preparation of the angiotensin II receptor antagonist is synthesized, isolated or otherwise obtained. The purity is tested to ensure suitability for use in a pharmaceutical preparation.

The active pharmaceutical ingredient in powder form is compressed under high pressure (e.g., for 10 to 100 M tons per cm^2 ; 25 to 50 M tons per cm^2) for a time sufficient for a glass transformation to take place.

The resultant discs can then be sorted by size and/or subjected to mechanical forces to modify the size or shape of the crystalline bodies. For example, the bodies can be passed through sieves to isolate bodies within desired size ranges, and can be ground, lathed, milled, cut (e.g., with a laser), etc., to reduce the size of alter the shape of the bodies.

Coatings.

Standard coating techniques well known in the art can be used to coat the large crystals. Examples include dipping, pan coating and spray coating. Care must be taken that the active pharmaceutical ingredient is not soluble in the solvent used in the polymeric coating. As discussed below, the coating can be a biodegradable polymer, a biocompatible polymer, or a biodegradable biocompatible polymer.

Biodegradable Polymers.

In some of the implementations of this invention, the large crystalline particles or implants are coated with biodegradable polymers. These polymers are well known in the art and examples include: naturally occurring polymers such as sugar phosphates, which are known to be biodegradable, and synthetic polymers such as polylactides and polyglycolic acids, which are also biodegradable. Lactic acid copolymers offer a degree of flexibility in choosing the life of a polymer matrix, because the half-life can be controlled by varying the amount and type of co-monomer used. Examples of suitable copolymers are glycolide, β -propiolactone, tetramethylglycolide, β -butyrolactone, tetramethylglycolide, β -butyrolactone, γ -butyrolactone, pivalolactone, intramolecular cyclic esters of α -hydroxybuteric acid, α -hydroxy, isovaleric acid, α -hydroxycaproic acid, α -hydroxy ethylbuteric acid, α -hydroxy isocaproic, α -hydroxy β -methyl valeric acid, α -hydroxy heptonic acid, α -hydroxy octanic acid, α -hydroxy deccanoic acid, α -hydroxy myristic acid, α -hydroxy stearic acid, α -hydroxy ligocenic acid, and β -phenol lactic acid. As also known in the art, polyglycolic acids can provide excellent biodegradable properties.

Biocompatible Polymers.

In some of the implementations of this invention, the large crystalline particles or implants are coated with biocompatible polymers. These polymers are well known in the art and examples include: acyl substituted cellulose acetates and alkyl derivatives thereof, partially and completely hydrolyzed alkylene-vinyl acetate copolymers; unplasticized polyvinyl chloride; cross-linked homo- and copolymers of polyvinyl acetate; cross-linked polyesters of acrylic and methacrylate; polyvinyl alkyl ethers; polyvinyl fluoride; silicone; polycarbonate; polyurethane; polyamide; polysulphones; styrene acrylonitrile copolymers; cross-linked poly(ethylene oxide); poly(alkylenes); poly(vinyl imidazole); poly(esters); poly(ethylene terephthalate); and chlorosulphonated polyolefins.

Dosage Forms.

In another aspect, the invention provides pharmaceutical preparations comprising one or more of the angiotensin II receptor antagonists described above, formulated

together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail herein, the pharmaceutical compositions of the invention are specially formulated for administration in the form of large crystalline particles in suspension or in the form of implants. These formulations are administered by parenteral administration, for example, by subcutaneous or intramuscular injection for suspensions, or by subcutaneous or intramuscular implantation for implants.

Because of the potential for embolic sequelae, intravenous or intra-arterial injections may not be appropriate, and subcutaneous (SC) or intramuscular (IM) injections may be safer. An injection volume of 0.1 to 10 cc, or 1 to 6 cc, can be used for IM injection, and a volume of 0.1 to 2 cc can be used for SC.

In some embodiments of the invention, the crystals of the angiotensin II receptor antagonist drug are suspended in a pharmaceutically acceptable carrier which serves as a dispersion medium to form a suspension for injection into a subcutaneous or intramuscular position for sustained pseudo-linear delivery over a period of greater than 1 week, greater than 2 weeks, greater than 4 weeks, or greater than 12 weeks.

Suspensions of large particles will tend to settle more rapidly than suspensions of small particles. Therefore, in some embodiments, a commercial product of the invention can be distributed as large crystalline particles in a dry form that can be suspended in a separately provided diluent prior to use. In other embodiments, a kit is provided containing separate containers of the large crystalline particles in a dry form and a diluent for forming the suspension prior to use. Alternatively, a multi-chambered product can be provided in which the large crystalline particles are contained in one chamber in a dry form and a diluent is contained in another chamber, such that a suspension is formed when the wall separating the chambers is ruptured and the particles and diluent are mixed. In addition to the diluent, appropriate suspending agents and surfactants well known in the art can be included.

When administered in the form of a suspension, a liquid carrier such as water, physiological saline solution, petroleum, oil (e.g., animal, plant or mineral oils, such as cottonseed, groundnut, corn, germ, olive, castor, peanut, mineral, soybean, sesame, or synthetic oils) can be used. The suspension form of the pharmaceutical can further contain inert diluents commonly used in the art, such as ethyl alcohol, isopropyl alcohol,

ethyl carbonate, ethyl acetate, ethyl oleate, benzyl alcohol, benzyl benzoate, glycols (e.g., ethylene glycol, propylene glycol, polyethylene glycol, 1,3-butylene glycol), glycerol, tetrahydrofuryl alcohol, dextrose or other saccharide solutions, and mixtures thereof. Suspensions, in addition to the active compounds, can contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan fatty acid esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. When administered in suspension form, the pharmaceutical composition can contain about 0.01 to 99% by weight of the crystals, 0.1 to 90% of the crystals, or about 1 to 50% of the crystal.

Pharmaceutically acceptable carriers can include solutions or mixtures of compounds such as sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; gelatin; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; alginic acid; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances routinely employed in pharmaceutical formulations.

In some embodiments of the invention, the crystals of the angiotensin II receptor antagonist drug are molded, shaped, compressed or formed into a solid implant for implantation into a subcutaneous or intramuscular position for sustained pseudo linear delivery over a period of greater than 1 week, greater than 2 weeks, greater than 4 weeks, or greater than 12 weeks. Such implants can include (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, hydroxypropylmethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; or (3) embedding compositions, such as polymeric substances and waxes.

Methods of Treatment.

In another aspect, the invention provides methods for treating a mammal suffering from or at risk of a condition for which administration of an angiotensin II receptor

antagonist is indicated. Such conditions include cardiovascular disorders, such as hypertension and heart failure and renal disease (Perico and Remuzzi 1998; Mimran, Ribstein et al. 1999; Houghton 2002). In general, the methods involve administering a pharmaceutical preparation of the invention to the mammal such that an effective amount of the active pharmaceutical ingredient is provided over a sustained period of time. The mammals can be humans, or can be nonhuman primates such as chimpanzees or other apes or monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like.

The sustained release formulation can be a coated or uncoated large crystal, or a coated or uncoated implant. In those embodiments in which the crystals or implants are coated, the coating can be a biodegradable polymer and/or a biocompatible polymer. In those embodiments in which the formulation includes large crystals, the crystals can be held in a suspension for injection.

In some embodiments, the formulations will be designed to provide sustained pseudo-linear delivery over a period of greater than 1 week, greater than 2 weeks, greater than 4 weeks, or greater than 12 weeks. The amount of the drug and the rate of delivery can be determined by the physician and/or pharmacist and will depend upon such factors as the potency of the active pharmaceutical ingredient, the severity of the condition, and the age, sex and weight of the subject. The rate of drug delivery is determined to provide an effective amount of the active pharmaceutical ingredient over a sustained period of time.

EQUIVALENTS

While this invention has been particularly shown and described with references to certain embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the invention.

REFERENCES

- Ansel, H., Allen LV, and Popovich NG. (1999). Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia, Lippincott Williams & Wilkins.
- Cadorniga, R., M. Burgos, et al. (1991). "In vitro evaluation of the dissolution rate of crystalline suspensions destined to intramuscular administration." Eur J Drug Metab Pharmacokinet Spec No 3: 379-84.
- Gennaro, A., Ed. (2000). Remington: The Science and Practice of Pharmacy. Philadelphia, Lippincott Williams & Wilkins.
- Houghton, A. (2002). "Angiotensin II receptor antagonists in chronic heart failure: where do they fit?" Drugs 62(10): p1433-40.
- Kaplan, E., X. Berrios, et al. (1989). "Pharmacokinetics of benzathine penicillin G: serum levels during the 28 days after intramuscular injection of 1,200,000 units." J Pediatr 115(1): p146-50.
- Mimran, A., J. Ribstein, et al. (1999). "Angiotensin II receptor antagonists and hypertension." Clin Exp Hypertens 21(5-6): p847-58.
- Mollmann, H., C. Bigalke, et al. (1977). "[Clinical and pharmacologic aspects of various betamethasone crystalline suspensions]." Fortschr Med 95(14): p972-8.
- Nichols, W. (2000). Hormones and Hormone Antagonists. Remington: The Science and Practice of Pharmacy. A. Gennaro. Philadelphia, Lippincott Williams & Wilkins: 1371.
- Perico, N. and G. Remuzzi (1998). "Angiotensin II receptor antagonists and treatment of hypertension and renal disease." Curr Opin Nephrol Hypertens 7(5): p571-8.
- Wong, P., A. Chiu, et al. (1988). "Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307)." J Pharmacol Exp Ther 247(1): p1-7.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.